Optimal dosing of enoxaparin in overweight and obese children.
Abdallah DerbalahStephen B DuffullCatherine M T SherwinKathleen M JobHesham S Al-SallamiPublished in: British journal of clinical pharmacology (2022)
A population PK model that describes the time course of anti-Xa activity of enoxaparin was developed in a paediatric population. Based on this model, a unified dosing regimen was proposed that will potentially improve the success rate of target attainment in overweight/obese patients without the need for patient body size categorisation. Therefore, prospective validation of the proposed approach is warranted.